Introduction {#s1}
============

The disastrous medical, social and economical burden of malaria in populations of sub-Saharan Africa is well recognized [@pone.0007611-Breman1], [@pone.0007611-Sachs1]. The development of an effective malaria vaccine would be an important addition to existing malaria control strategies.

The pre-erythrocytic stage *Plasmodium falciparum* antigen RTS,S is the furthest advanced malaria vaccine candidate in clinical development [@pone.0007611-Girard1]. A collaborative partnership involving several malaria research institutions worldwide, GlaxoSmithKline Biologicals (GSK), the PATH Malaria Vaccine Initiative and the Malaria Clinical Trial Alliance was developed with the goal to develop RTS,S/AS for the Expanded Program on Immunisation (EPI) of the World Health Organization [@pone.0007611-Malkin1].

RTS,S is a hybrid molecule recombinantly expressed in yeast, in which the central tandem repeat and carboxyl-terminal region of the circumsporozoite protein are fused to the N-terminal of the S-antigen of the Hepatitis B virus, creating a particle that also includes the unfused S-antigen. RTS,S is formulated in Adjuvant Systems which enhance the ability of the vaccine to induce a strong immune response. The AS02 Adjuvant System contains an oil-in-water emulsion, monophosphoryl lipid A (MPL), and QS21, a natural saponin molecule purified from the bark of the South American tree, Quillaja saponaria. Following Phase I studies, a Phase IIb efficacy trial conducted in about two thousand Mozambican children aged 1--4 years showed that the vaccine reduced the risk of clinical malaria (vaccine efficacy of 35%) and of severe malaria (vaccine efficacy of 49%) over a period of 18 months [@pone.0007611-Alonso1]. In infants from the same study area receiving the vaccine at 10, 14, and 18 weeks of age, the risk of infection was reduced by 65% over three months after the third and final dose and the risk of clinical disease by 35% over a six-month period following the first dose [@pone.0007611-Aponte1].

In addition to the oil-in-water emulsion of AS02, an alternative Adjuvant System based on liposomes and containing the same amounts of MPL and QS21 has been developed (AS01). An initial study in malaria-naïve adults showed that RTS,S/AS01 had a similar safety profile, a higher humoral immunogenicity, a favorable Th1 cell mediated immune profile and a trend towards higher vaccine efficacy in comparison to RTS,S/AS02 [@pone.0007611-Kester1].

AS01 and AS02 have been formulated in both adult (AS01~B~, AS02~A~) and pediatric (AS01~E~, AS02~D~) dosages. In the large Phase II trial in Mozambique [@pone.0007611-Alonso2] the pediatric dosage was obtained by administering half of the adult dose (i.e. 0.25 mL of AS02~A~). In order to comply with EPI standards, the vaccine volume was changed to 0.5 mL. The equivalency of 0.25 mL AS02~A~ and 0.5 mL AS02~D~, both containing 25 µg RTS,S, in terms of safety and immunogenicity was shown in children in Mozambique [@pone.0007611-Macete1].

As part of an age de-escalation step in the RTS,S clinical vaccine development plan, we conducted a phase II, randomized, double-blind study to assess the safety and immunogenicity of RTS,S/AS01~E~ and RTS,S/AS02~D~ in children aged 18 months to 4 years living in Gabon. The resulting data will make a significant contribution in deciding which Adjuvant System to use for a large scale large efficacy trial with RTS,S/AS. Furthermore, we hoped to obtain information on the immunogenic effect of the third dose, compared to two doses, and the effect of previous hepatitis B immunisation on the anti-CS immune response.

Materials and Methods {#s2}
=====================

The protocol for this trial \[<http://clinicaltrials.gov/>: NCT00307021\] and supporting CONSORT checklist are available as supporting information; see [Checklist S1](#pone.0007611.s001){ref-type="supplementary-material"} and [Protocol S1](#pone.0007611.s002){ref-type="supplementary-material"}.

Ethics statement {#s2a}
----------------

The study protocol was approved by the ethics committee of the International Foundation of the Albert Schweitzer Hospital of Lambaréné and the Western Institutional Review Board, USA. The trial was undertaken according to the International Conference on Harmonisation of Good Clinical Practice guidelines and was monitored by GSK Biologicals, Rixensart, Belgium. A local safety monitor and a data and safety monitoring board closely reviewed the conduct and results of the trial. After vaccination of Dose 1 and Dose 2 of the first 30 subjects, the data and safety monitoring board reviewed the seven day post vaccination safety data in order to decide on the continuation to the next dose.

Study site {#s2b}
----------

The study lasted from April 2006 to August 2007 and was conducted at the Medical Research Unit (MRU) of Albert Schweitzer Hospital in Lambaréné, located in the central part of Gabon. Malaria transmission is mainly attributable to *Plasmodium falciparum*. *Anopheles gambiae* is the main vector and transmission is perennial, moderate to high in intensity [@pone.0007611-Wildling1], with an average entomological inoculation rate (EIR) around 50 infective bites per person per year [@pone.0007611-Sylla1].The incidence of malaria in children was around 1.5 per child per year in 1999 [@pone.0007611-Lell1], but has decreased in recent years [@pone.0007611-Grobusch1]. Long-lasting insecticide-treated bednets are provided free of charge for pregnant women and children under 12 months of age during national health campaigns. A study carried out in 2005 revealed a high proportion of the population sleeping under bednets, however these often had never been impregnated (94%) and had holes (20%) [@pone.0007611-Goesch1].

Coverage of routine EPI vaccination in the study area is above national average [@pone.0007611-United1] with a recent survey showing 87% of children having received three doses of DTP at 4 months of age and 74% had received measles vaccination at 9 months of age (Bertrand Lell, unpublished data).

Study design {#s2c}
------------

This was a Phase II randomized, double-blind trial to describe safety, reactogenicity and immunogenicity of RTS,S/AS01~E~ and RTS,S/AS02~D~ when administered intramuscularly with a 0, 1, 2 month vaccination schedule in children aged 18 months to 4 years. The primary objectives were to assess the occurrence of serious adverse events from the time of first vaccination until one month post Dose 3 and to establish the non-inferiority of anti circumsporozoite antibodies titers of RTS,S/AS01~E~ compared to RTS,S/AS02~D~ at one month post Dose 3. A SAE was defined per protocol as any untoward medical occurrence that was fatal, life-threatening, required hospitalization, led to disability or incapacity, or was judged by investigators as being medically important enough to be reported as serious. In order to maximize data capture about seizures, all seizures occurring within 30 days of vaccination had to be reported as SAEs. Data on seizures occurring within 7 days post vaccination were collected in a standard way according to Brighton collaboration guidelines [@pone.0007611-Bonhoeffer1].

Secondary objectives included reactogenicity, anti-HBs antibody response and anti-CS response, and the 1 year post last dose safety and immunogenicity follow up.

Study vaccines {#s2d}
--------------

RTS,S/AS02~D~ (0.5 mL) and RTS,S/AS01~E~ (0.5 mL) comprise the RTS,S antigen presented as a lyophilized pellet, which is reconstituted prior to injection with 0.5 mL of AS02~D~ or AS01~E~ liquid Adjuvant Systems containing MPL and QS21 immunostimulants. The RTS,S pellet and Adjuvant Systems are in sterile glass vials, stored between +2 and +8°C.

Study population {#s2e}
----------------

We included children aged 18 months to 4 years (up to but not including 5th birthday) who were permanent residents in Lambaréné. Written informed consent or, in case of illiteracy, a thumb print in presence of a literate witness was obtained for all screened children from both parents/guardians, or at least one parent in case the other could not be reached. Major exclusion criteria were history of allergic disease, a weight for age Z-score less than −2, and clinically significant chronic or acute disease.

Randomization and blinding {#s2f}
--------------------------

Eligible children were allocated to a treatment group on the day of first vaccination. The randomization list, designed as a single block randomization, was generated at GSK Biologicals, Rixensart, using SAS® statistical software. Safety and immunogenicity endpoints were evaluated in a double-blind manner as the investigators and their parent(s)/guardian(s) were unaware which vaccine was administered to a particular child. Only two study nurses and an observer responsible for vaccine storage, preparation and quality control were aware of the vaccine assignment. They were not involved in other aspects of the trial or patient care. Code break envelopes with individual vaccine allocation were kept locally with a local safety monitor. A second copy was kept at GSK Biologicals, Rixensart, Belgium. There was no case of emergency unblinding during the study. Vaccine preparation, vaccination and clinical observation were performed in separated rooms. Vaccine preparation consisted of reconstituting the lyophilized antigen using the liquid Adjuvant System fraction, stored in separate vials, to a final volume of 0.5 mL.

Study procedures {#s2g}
----------------

Before screening, the parents or guardian was issued a bednet containing an impregnation kit and instructions on its use. Screening procedures included a brief medical history, examination and blood sampling for hematology (hemoglobin, white cell count, and platelets), and biochemistry (ALT, creatinine, and bilirubin). The past Hepatitis B immunization status as documented on the children\'s national immunization cards was recorded. Vaccine administration was by slow IM injection in the left deltoid. After vaccination, children were observed for at least one hour by investigators trained in pediatric emergency care and thereafter visited by field workers daily for the next six days. General symptoms and those specific to RTS,S vaccination in particular were assessed. These 'solicited symptoms' (local symptoms: pain, swelling; generalized symptoms: drowsiness, fever, irritability, loss of appetite) were graded and recorded on diary cards. Grade 3 symptoms were defined, for pain, when a child cries when limb is moved or spontaneously painful; for swelling when larger than 20 mm; and for general symptoms, as those that prevent normal activities. Unsolicited adverse events were documented over a period of 30 days post vaccination and serious adverse events were recorded up to one year post last vaccine dose. Local standard medical care was provided free of charge throughout the study.

Laboratory methods {#s2h}
------------------

As part of safety assessments, venous blood samples were collected for hematology (hemoglobin, white cell count, platelets; ABX Pentra 60 analyzer, France) and biochemistry (ALT, creatinine and bilirubin; Cobra Mira Plus analyzer, Switzerland) determination on Day 6 after Dose 1 and one month post Dose 3.

Blood samples for the measurement of anti-circumsporozoite protein (CS) and antibody to the hepatitis B surface antigen (anti-HBsAg) were collected at screening and one month post Dose 2 and 3, and at study month 14. Serological responses to CS repeats (anti R32LR) were assessed by standard ELISA methodology using a plate adsorbed R32LR antigen with a standard reference antibody as a control with concentrations reported as EU/mL. Antibody titers to hepatitis B surface antigen were measured using an ELISA immunoassay, developed at GSK Biologicals, Rixensart with concentrations reported in mIU/mL. All ELISA assays were performed in a GLP ICH validated laboratory.

Populations analyzed {#s2i}
--------------------

The ITT cohort for analysis of safety included all subjects who received at least one vaccine dose. The ATP cohort for analysis of immunogenicity included all evaluable subjects (i.e., those meeting all eligibility criteria, complying with the procedures defined in the protocol, having no elimination criteria during the study) for whom data concerning immunogenicity endpoint measures were available.

Statistical analysis {#s2j}
--------------------

A sample size of 75 evaluable subjects per group was determined to have 90% power to demonstrate non-inferiority of RTS,S/AS01~E~ versus RTS,S/AS02~D~ in terms of anti-CS immune response (upper limit of 95% CI of the GMT ratio RTS,S/AS02~D~ versus RTS,S/AS01~E~ below 3.0), assuming a log standard deviation of 0.9 in both groups, and an alpha level of 2.5%. To allow for loss to follow-up, 90 children were included in each group. The Geometric Mean Titers (GMTs) calculations were performed by taking the anti-log of the mean of the log10 titer transformations. The 95% CI of the ratio of anti-CS GMTs was calculated using a one-way ANOVA model on the logarithm transformation of the titers. Antibody titers below the cut-off of the assay were given an arbitrary value of half the cut-off for the purpose of GMT calculation. Subjects with anti-HBs antibody titers greater than 10 mIU/mL were considered protected.

Results {#s3}
=======

Out of 280 children screened for eligibility, 180 were randomized into two intervention groups. The demographic characteristics were similar in the two groups, with a mean age of 39.6 (SD: 11.5) months and 39.3 (SD: 11.2) months and with 36 (40%) and 52 (58%) females in the RTS,S/AS01~E~ and the RTS,S/AS02~D~ group, respectively. [Figure 1](#pone-0007611-g001){ref-type="fig"} shows the disposition of subjects in the study.

![Subject disposition.](pone.0007611.g001){#pone-0007611-g001}

Safety {#s3a}
------

The vaccine safety was analyzed based on the 180 children of the ITT population. Between first vaccination and 1 month post Dose 3, three children in the RTS,S/AS01~E~ group and four in the RTS,S/AS02~D~ group experienced at least one serious adverse event ([Table 1](#pone-0007611-t001){ref-type="table"}),. Two children were excluded from further vaccination due to a serious adverse event, diagnosed with conditions that would have precluded study participation if found before enrolment: one case of newly diagnosed sickle cell, and one case of a simple febrile convulsion that occurred 18 days postvaccination, in the context of an uncharacterized acute febrile illness that evolved favorably over 3 days. The other serious adverse events included anemia, asthma, gastroenteritis, pneumonia, and incarcerated umbilical hernia. Between first vaccination and study Month 14, 16 subjects experienced at least one serious adverse events (8 in each group) ([Table 1](#pone-0007611-t001){ref-type="table"}). None of these events were considered related to the study vaccine and all subjects recovered.

10.1371/journal.pone.0007611.t001

###### Listing of SAEs that occurred during the whole study period.

![](pone.0007611.t001){#pone-0007611-t001-1}

  Group      Subject No.   Gender   Age at onset (Month)        Event (Preferred term)         Onset (days post Dose)   Vaccine relatedness
  --------- ------------- -------- ---------------------- ----------------------------------- ------------------------ ---------------------
  AS01~E~         9          M               33                   Febrile convulsion                18d post D2                 No
                                                                        Pyrexia                     17d post D2                 No
                 66          M               58                        Hydrocele                    272d post D3                No
                                                                       Phimosis                     272d post D3                No
                 104         M               37                      Constipation                   97d post D3                 No
                 115         M               57                       Bronchitis                    286d post D3                No
                 125         F               28                        Pneumonia                    216d post D3                No
                 181         M               30                         Anaemia                      7d post D3                 No
                                                                        Asthma                       7d post D3                 No
                                                                       Pneumonia                     6d post D3                 No
                 234         F               42                         Anaemia                     101d post D3                No
                                                                        Malaria                     96d post D3                 No
                 277         F               51                       Hepatitis A                    2d post D2                 No
                                                                  Sickle cell anaemia                5d post D2                 No
  AS02~D~         1          M               33              Umbilical hernia, obstructive          21d post D2                 No
                 72          F               34                         Asthma                      81d post D3                 No
                                                           Lower respiratory tract infection        77d post D3                 No
                                                                      Pharyngitis                   77d post D3                 No
                 88          F               25                     Gastroenteritis                 26d post D3                 No
                                             28                   Burns second degree               122d post D3                No
                 117         F               40                         Anaemia                     47d post D3                 No
                                                                   Cerebral malaria                 42d post D3                 No
                                             42             Plasmodium falciparum infection         92d post D3                 No
                 138         F               27                     Gastroenteritis                 30d post D3                 No
                 141         M               22                     Gastroenteritis                  9d post D3                 No
                 161         M               30                         Asthma                      126d post D3                No
                                             33                        Pneumonia                    230d post D3                No
                 198         M               38                        Epilepsy                     84d post D3                 No
                                             44                        Epilepsy                     238d post D3                No
                                             45                        Epilepsy                     273d post D3                No

Solicited adverse events are summarized in [Table 2](#pone-0007611-t002){ref-type="table"}. Mild local solicited symptoms were frequent with pain being reported following 48% and 54% of doses of RTS/AS01~E~ and RTS,S/AS02~D~ respectively and swelling being present following 32% and 37% of doses of RTS/AS01E and RTS,S/AS02~D~. Grade 3 symptoms were rare, being present only after two vaccine doses administered. These were two cases of swelling over 20 mm, one in each study group. There was an increase in the frequency of local symptoms for subsequent doses for both groups. General solicited symptoms were considerably less frequent, with loss of appetite observed most frequently, after 44 (17%) doses of RTS,S/AS01~E~ and 46 (18%) of RTS,S/AS02~D~ doses. Frequencies of general solicited symptoms were similar between the intervention groups and no increase in frequency for progressive doses was found. No grade 3 solicited generalized symptoms were observed following vaccination. Previous Hepatitis B vaccination did not significantly affect the incidence of solicited symptoms following vaccination with either study vaccine (data not shown).

10.1371/journal.pone.0007611.t002

###### Solicited symptoms per dose during a 7-days post-vaccination period.

![](pone.0007611.t002){#pone-0007611-t002-2}

                                      RTS,S/AS01~E~     RTS,S/AS02~D~           
  ---------------------------------- --------------- -------------------- ----- --------------------
  **[Generalized symptoms]{.ul}:**                                              
  Drowsiness, overall                      261         17 (7%; 4--10%)     262     13 (5%; 3--8%)
  Fever, overall                           261          15 (6%; 3--9%)     262    23 (9%; 6--13%)
  Irritability, overall                    261          6 (2%; 1--5%)      262     8 (3%; 1--6%)
  Loss of appetite, overall                261        44 (17%; 13--22%)    262   46 (18%; 13--23%)
  **[Local symptoms:]{.ul}**                                                    
  Pain, overall                            261        126 (48%; 42--55%)   262   142 (54%; 48--60%)
  Dose 1                                   90         19 (21%; 13--31%)    90    32 (36%; 26--46%)
  Dose 2                                   88         34 (39%; 28--50%)    87    34 (39%; 29--50%)
  Dose 3                                   83         73 (88%; 79--94%)    85    76 (89%; 81--95%)
  Swelling, overall                        261        83 (32%; 26--38%)    262   96 (37%; 31--43%)
  Dose 1                                   90           5 (6%; 2--13%)     90     13 (14%; 8--23%)
  Dose 2                                   88         21 (24%; 15--34%)    87    22 (25%; 17--36%)
  Dose 3                                   83         57 (69%; 58--78%)    85    61 (72%; 61--81%)

N: number of vaccine doses administered.

Overall, unsolicited adverse events in the 30 days post vaccination period occurred in 78.9% of the participants of the RTS,S/AS01~E~ group and in 82.2% of the RTS,S/AS02~D~ group ([Table 3](#pone-0007611-t003){ref-type="table"}). The most frequently observed unsolicited symptoms were upper respiratory tract infection and other common pediatric conditions. None were considered to be causally related to the study vaccines.

10.1371/journal.pone.0007611.t003

###### Occurrence of unsolicited symptoms within the 30-day (Days 0--29) post-vaccination period.

![](pone.0007611.t003){#pone-0007611-t003-3}

                                       RTS,S/AS01~E~   RTS,S/AS02~D~                                   
  ----------------------------------- --------------- --------------- ------ ------ ---- ------ ------ ------
  At least one event                        71             78.9        69.0   86.8   74   82.2   72.7   89.5
  Diarrhoea                                  5              5.6        1.8    12.5   9    10.0   4.7    18.1
  Pyrexia                                    5              5.6        1.8    12.5   5    5.6    1.8    12.5
  Acarodermatitis                            5              5.6        1.8    12.5   6    6.7    2.5    13.9
  Bronchitis                                 9             10.0        4.7    18.1   11   12.2   6.3    20.8
  Gastroenteritis                            4              4.4        1.2    11.0   9    10.0   4.7    18.1
  Helminthic infection                      17             18.9        11.4   28.5   11   12.2   6.3    20.8
  Nasopharyngitis                           41             45.6        35.0   56.4   41   45.6   35.0   56.4
  Otitis media                               5              5.6        1.8    12.5   2    2.2    0.3    7.8
  Staphylococcal skin infection             10             11.1        5.5    19.5   13   14.4   7.9    23.4
  Tinea capitis                              6              6.7        2.5    13.9   5    5.6    1.8    12.5
  Upper respiratory tract infection          5              5.6        1.8    12.5   4    4.4    1.2    11.0

Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MEDDRA Preferred Term within the 30-day (Days 0--29) post-vaccination period, for events that occurred in over 5% of the patient in at least one of the study groups.

N = number of subjects with at least one administered vaccine dose.

n/% = number/percentage of subjects reporting at least once the symptom.

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit.

Out of range hematological and biochemical values were observed in 21 measurements. No Grade 3 abnormalities were observed. The abnormal values were all judged not to be clinically significant and there was no imbalance between vaccine groups.

Immunogenicity {#s3b}
--------------

The antibody response was evaluated in the ATP population, consisting of 170 children, balanced by group. The primary immunogenicity endpoint of the trial was met: at 30 days post Dose 3, the ratio of GMT titers (AS02~D~/AS01~E~) was 0.88 (95% CI: 0.68--1.15), with an upper confidence interval below the pre-defined non-inferiority cut-off of three. Both vaccines elicited a strong specific immune response after Dose 2 and Dose 3 ([Table 4](#pone-0007611-t004){ref-type="table"}). For both vaccines, the antibody titers were significantly higher after the third dose compared to the first two doses. There was a trend towards higher anti-CS GMTs in the recipients of RTS,S/AS01~E~ compared to the RTS,S/AS02~D~ group at post Dose 2 and post Dose 3, but these were of similar magnitude at study Month 14.

10.1371/journal.pone.0007611.t004

###### Anti-CS and anti-HBs antibody titers after each dose and at 12 months post Dose 3.

![](pone.0007611.t004){#pone-0007611-t004-4}

                                     RTS,S/AS01~E~   RTS,S/AS02~D~                                      
  --------------------------------- --------------- --------------- ------------------ ---- ----------- ------------------
  **[Anti-CS antibodies:]{.ul}**                                                                        
  **Screening, all**                      85            **0.3**        **0.3--0.3**     84    **0.3**      **0.3--0.3**
  \- pre HBV                              40              0.3            0.3--0.3       40      0.3          0.3--0.3
  \- no pre HBV                           37              0.3            0.3--0.3       39      0.3          0.2--0.3
  **Post Dose 2, all**                    74            **80**         **63--101**      74    **58**        **46--73**
  \- pre HBV                              35              109            79--152        34      81           57--114
  \- no pre HBV                           31              50              35--71        36      44            33--59
  **Post Dose 3, all**                    73            **207**        **172--250**     73    **183**      **151--223**
  \- pre HBV                              35              238            187--302       36      201          145--278
  \- no pre HBV                           31              170            122--238       33      164          128--209
  **Month 14, all**                       58            **16**          **12--21**      54    **18**        **13--26**
  \- pre HBV                              29              15              10--23        29      18            10--32
  \- no pre HBV                           23              17              10--28        21      17            10--29
  **[Anti-HBs antibodies:]{.ul}**                                                                       
  **Screening, all**                      85            **45**          **25--80**      84    **19**        **12--29**
  \- pre HBV                              40              284            127--637       40      61           30--124
  \- no pre HBV                           37               8              5--11         39       6             4--9
  **Post Dose 2, all**                    74           **9228**      **4676--18210**    74   **3838**     **2036--7237**
  \- pre HBV                              35             79610        43152--146869     34     22946       10115--52053
  \- no pre HBV                           31             1095           562--2135       36      770         385--1540
  **Post Dose 3, all**                    73           **26330**     **16578--41821**   73   **20068**   **13636--29533**
  \- pre HBV                              35             94879        56708--158741     36     48279       28412--82038
  \- no pre HBV                           31             7982          5534--11511      33     8292        5233--13138
  **Month 14, all**                       58           **6769**      **4338--10561**    54   **5236**     **3421--8012**
  \- pre HBV                              29             17851         10235--31136     29     8408        4467--15825
  \- no pre HBV                           23             2539           1723--3746      21     3100         1708--5625

Values are geometric mean titers and 95% confidence intervals expressed in EU/mL. N values for pre HBV and no pre HBV do not match up to the total due to some missing values on the pre HBV status.

In both study groups, an equivalent proportion of children had previously received hepatitis B vaccination. After Dose 2 and Dose 3 of experimental vaccine, anti-CS antibody GMTs were higher in the children who had been previously vaccinated with at least one dose of hepatitis B vaccine compared to those who had not been previously vaccinated ([Table 4](#pone-0007611-t004){ref-type="table"}, [Figure 2](#pone-0007611-g002){ref-type="fig"}). No difference in GMTs was apparent at study Month 14.

![The effect of previous hepatitis B vaccination on anti-CS antibodies.\
Boxplot graph of anti-CS responses. Represents Q25, median, Q75, highest and lowest observation below/above 1.5 times interquartile range and individual data points below/above 1.5 times interquartile range. GMTs are indicated by +.](pone.0007611.g002){#pone-0007611-g002}

Both RTS,S/AS01~E~ and RTS,S/AS02~D~ were highly immunogenic for anti-HBs antibodies. Over 98% of the children had anti-HBs titers above the seroprotection level following Dose 2 and all children were protected following Dose 3, with no difference between groups. There was a trend towards higher anti-HBs GMTs in the recipients of RTS,S/AS01~E~ compared to the RTS,S/AS02~D~ group, following both Dose 2 and Dose 3, with a AS02~D~/AS01~E~ GMT ratio of 0.76 (95% CI: 0.42--1.39) after the third dose ([Table 4](#pone-0007611-t004){ref-type="table"}, [Figure 3](#pone-0007611-g003){ref-type="fig"}).

![The effect of previous hepatitis B vaccination on anti-HBs antibodies.\
Boxplot graph of anti-HBs responses. Represents Q25, median, Q75, highest and lowest observation below/above 1.5 times interquartile range and individual data points below/above 1.5 times interquartile range. GMTs are indicated by +.](pone.0007611.g003){#pone-0007611-g003}

Children who had previously received a hepatitis B vaccine had higher anti-HBs GMTs at screening than those who were not vaccinated and the difference remained statistically significant at all three timepoints for either vaccine. Post Dose 3, GMTs for recipients of RTS,S/AS01~E~ were 94879 mIU/mL and 7982 mIU/mL and for recipients of RTS,S/AS02~D~ were 48279 mIU/mL and 8292 mIU/mL with previous hepatitis B vaccination and without previous hepatitis B vaccination, respectively ([Table 4](#pone-0007611-t004){ref-type="table"}).

Discussion {#s4}
==========

A series of clinical studies performed with more than a thousand vaccine recipients have established the RTS,S/AS02 candidate vaccine to have an promising safety profile and to be well-tolerated. These studies were conducted in malaria-naïve and semi-immune adults as well as African children, with the first demonstration of efficacy for a malaria candidate vaccine [@pone.0007611-Alonso1], [@pone.0007611-Alonso2], [@pone.0007611-Bojang1]--[@pone.0007611-Macete2]. Pre-clinical data suggests that RTS,S/AS01 may be a better malaria vaccine candidate [@pone.0007611-Stewart1]. A challenge study conducted in the United States showed that RTS,S/AS01, as compared to RTS,S/AS02, induced higher levels of anti-CS antibodies and CS-specific T-cells, and a trend towards higher protection against infection following experimental sporozoite challenge. The safety profile of both vaccines was similarly favorable [@pone.0007611-Kester1]. The safety and high immunogenicity of the RTS,S/AS01 formulation was confirmed in malaria-exposed adults in Kenya [@pone.0007611-Polhemus1]. Here, the first use of RTS,S associated with the AS01 Adjuvant System in children is reported.

In the present study, both vaccines were well tolerated. In both groups, patterns of non-serious and serious adverse events were in accordance with general morbidity observed in this population. There were no unsolicited adverse events related to vaccination. Vaccination induced no hematological or biochemical abnormalities. The vast majority of solicited symptoms consisted of mild pain at the injection site, confirming results of previous RTS,S/AS01 and RTS,S/AS02 studies. The frequency of local solicited symptoms (pain and swelling) was dose related and progressively increased from Dose 1 to 3 in both vaccines groups. This trend had been reported in previous trials with RTS,S/AS02 [@pone.0007611-Doherty1], [@pone.0007611-Macete2], as well as with other vaccines [@pone.0007611-Pichichero1], showing that this is not specific to the malaria candidate vaccine or specific Adjuvant System technology, and is probably linked to a local reaction between antigen and immune effectors like antibodies and primed T-cells. Importantly, these reactions remained moderate in intensity even after the third dose. In summary, all safety data generated in this trial show that both formulations of the RTS,S/AS candidate vaccine have a favorable safety profile. Larger studies are needed to allow detection of potential rare events.

Our study clearly confirms our primary hypothesis, i.e., the non-inferiority of RTS,S/AS01~E~ compared to RTS,S/AS02~D~ in its ability to induce anti-CS antibodies. In fact, an early trend towards higher anti-CS GMTs in recipients of RTS,S/AS01~E~ was found. The trend toward a stronger immune response using the AS01~E~ Adjuvant System was also observed for anti-HBsAg titers. The results also show the enhancement effect of a third vaccine dose compared to a two-dose regimen in eliciting an anti-CS immune response. The relationship between anti-CS immune response and protection induced against malaria is complex and not yet fully characterized, as no protective threshold has been defined. While a consistent association between higher (vs. lower) anti-CS response and protection against *P. falciparum* infection was seen in challenge studies [@pone.0007611-Kester2], [@pone.0007611-Stoute1], [@pone.0007611-Kester3] and in field trials with active detection of infection [@pone.0007611-Aponte1], such an association was not found with malaria disease, as captured in a passive case detection system [@pone.0007611-Alonso2]. More thorough investigation of immune responses to RTS,S/AS candidate vaccines, including in efficacy studies, are underway and may contribute to better characterisation of the relationship between the immunity induced and protection.

According to national guidelines of Gabon, Hepatitis B vaccine is administered routinely as part of the EPI programme. However, supply chain ruptures, migration, and other factors lead to a partial immunization of a large proportion of the population and almost half of the children in this study had not received any hepatitis B vaccine at recruitment. Interestingly, we found that children with prior immunization against hepatitis B had a stronger immune response post-vaccination not only against HBsAg but against CS as well. Neonatal hepatitis B vaccination may therefore be favorable to early RTS,S-induced protection against malaria in case of integration of an RTS,S-based vaccine in an EPI program that includes neonatal hepatitis B vaccination.

It is unclear how previous HBs-induced immune responses enhance the CS-specific response but it is most likely related to the covalently bound CS segment and HBs fusion protein present in RTS,S. The following non exclusive hypothetical mechanisms may occur: (i) circulating anti-HBs antibodies may be favorable to CS antigen capture by antigen-presenting cells and following T-cell and B-cell priming; (ii) HBs-primed B-cells expressing anti-HBs surface antibodies may capture the RTS,S antigen and, given their antigen presentation capacities, be efficient antigen presenting cells for CS-specific T-cell priming; (iii) HBs-specific CD4 memory T-cells induced by previous vaccination may provide more rapid T-cell help to CS-specific B cells upon antigen re-stimulation by the HBsAg present in RTS,S.

Having been previously vaccinated with at least one Hepatitis B vaccine dose was associated with increased anti-HBs responses post vaccination dose 2 and dose 3, with both RTS,S formulations, indicating the absence of exhaustion of the immune response upon repeated exposure to the HBs vaccine antigen.

As a result of the encouraging result of the present trial, given the favorable safety profile and the indication of superior immunogenicity of RTS,S/AS01~E~ compared to RTS,S/AS02~D~, further development of this vaccine candidate is ongoing. Studies aiming at confirmation of safety, further age de-escalation, schedule optimization, assessment of efficacy against malaria, and interaction of RTS,S/AS01~E~ with EPI vaccines are currently being performed in various parts of Africa.
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